MyMedicalRecords Enters Into Agreement With WebMD and Initiates Service Against Jardogs LLC, a Subsidiary of Allscripts

MyMedicalRecords Enters Into Agreement With WebMD and Initiates Service Against 
Jardogs LLC, a Subsidiary of Allscripts 
LOS ANGELES, CA -- (Marketwired) -- 06/07/13 --  MMRGlobal, Inc.
(OTCQB: MMRF) ("MMR") has announced that as previously disclosed,
MyMedicalRecords, Inc., a wholly owned subsidiary of MMRGlobal, sued
WebMD Health Corp. and WebMD Health Services Group, Inc.
(collectively, "WebMD") in federal district court for patent
infringement. MMR has entered into a written agreement with WebMD to
dismiss the case without prejudice to re-filing the same case again,
in order to continue to try and resolve the matter without the timing
constraints imposed by the lawsuit. As the dismissal is without
prejudice, MMR retains the right to re-file the litigation at any
time. The complaint was filed in the United States District Court for
the Central District of California, case number CV 13-00979
(ODW/SHx), on February11, 2013, and is available on the court's
website http://www.pacer.gov/.   
Robert H. Lorsch, CEO of MMRGlobal, said, "As a former arbitrator for
the American Arbitration Association, I learned from firsthand
experience that resolving disputes privately at a table is always my
preferred course of action when compared to spending millions of
dollars in legal fees over years in a courtroom. As the inventor of
MMR's health IT patent portfolio, I see this announcement as a
positive development for the Company. The purpose in filing our
patents has always been to protect MMR's constitutional right to own
property and sell the products and services which include our
patented IP. We hope this will be the first of many similar
opportunities to build business relationships at the negotiating
table with hospitals, providers, vendors and others who may be
infringing on the Company's IP."  
The Company also announced that domestically, it has initiated
service of its patent infringement complaint recently filed against
Jardogs LLC, a subsidiary of Allscripts, case number CV 13-3560,
which can also be found at http://www.pacer.gov/. According to the
complaint, Jardogs provides health information services to consumers
and healthcare providers and Jardogs, while infringing on MMR's
patent, also has induced others including Allscripts, distributors
,
agents, resellers and users to infringe one or more claims of the
patent. 
Internationally, MMR has retained the Sydney, Australia-based law
firm of Rockwell Olivier, which earlier this week advised the
National E-Health Transition Authority in Australia ("NEHTA") that
based on preliminary investigations, the personally controlled
electronic health record system deployed by NEHTA appears in many
respects to be using the same methods as MMR's MyMedicalRecords
Australian patents, specifically numbers 2006202057 and 2008202401. 
"While we continue to pursue additional licensing opportunities, we
remain confident in the value of our seven issued U.S. patents and
global patents in 12 countries around the world. MMR remains
committed to aggressively leveraging our portfolio of health
information technology patents in the marketplace to obtain the
highest value for our stockholders, employees and vendors," Lorsch
added. 
MMR is a leading provider of Personal Health Records,
MyEsafeDepositBox storage solutions, and MMRPro document management
and imaging systems for healthcare professionals. The MMR Patent
Portfolio includes seven issued U.S. patents -- U.S. Patent Nos.
8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and
8,321,240 -- as well as additional applications and continuation
applications including nearly 400 claims. The patents involve
inventions pertaining to Personal Health Records, Patient Portals and
other Electronic Health Record systems. MMR also has been granted
patents and has other pending applications in countries of commercial
interest including Australia, Singapore, New Zealand, Mexico, Japan,
Canada, Hong Kong, South Korea, Israel, and European nations. The
Company's health IT patent portfolio was the subject of a May 2, 2013
report on Personal Health Records that concluded that the value of
the Company's U.S. patents could reach between $800 million to $1.1
billion in revenue (available at
http://michaelbass.com/PDF/Patent_Valuation.pdf).  
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions, serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, and professional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, the Company
acquired intellectual property biotech assets that include anti-CD20
antibodies and data and samples from its FavId(TM)/Specifid(TM)
vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's
lymphoma. To learn more about MMRGlobal, Inc. visit
www.mmrglobal.com. View demos and video tutorials of the Company's
products and services at www.mmrtheater.com. 
Forward-Looking Statements 
 All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property enforcement actions, infringement
claims or litigation, intellectual property licenses, and future
performance, management's expectations, beliefs, intentions,
estimates or projections, constitute "forward-looking statements."
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements.
Some can be identified by the use of words (and their derivations)
such as "need," "possibility," "potential," "intend," "offer,"
"development," "if," "negotiate," "when," "begun," "believe,"
"achieve," "will," "estimate," "expect," "maintain," "plan," and
"continue," or the negative of these words. Actual outcomes and
results of operations and the timing of selected events may differ
materially from the results predicted, and any reported results
should not be considered as an indication of future performance. Such
statements are necessarily based on assumptions and estimates and are
subject to various risks and uncertainties, including those relating
to the possible invalidity of the underlying assumptions and
estimates and possible changes or developments in economic, business,
industry, market, legal and regulatory circumstances and conditions
and actions taken or omitted to be taken by third parties, including
customers, suppliers, business partners, potential licensees,
co
mpetitors and legislative, judicial and other governmental
authorities and officials. Factors that could cause or contribute to
such differences include, but are not limited to: unexpected outcomes
with respect to intellectual property enforcement actions, claims of
intellectual property infringement and general intellectual property
litigation; our ability to maintain, develop, monetize and protect
our patent portfolio for both the Company's health IT and
biotechnology intellectual property assets in the U.S. and
internationally; the timing of milestone payments in connection with
licensing our intellectual property; our ability to establish and
maintain strategic relationships; changes in our relationships with
our licensees; the risk the Company's products are not adopted or
viewed favorably by the healthcare community and consumer retail
market; business prospects, results of operations or financial
condition; risks related to the current uncertainty and instability
in financial and lending markets, including global economic
uncertainties; the timing and volume of sales and installations; the
length of sales cycles and the installation process; the market's
acceptance of new product and service introductions; competitive
product offerings and promotions; changes in government laws and
regulations including the 2009 HITECH Act and changes in Meaningful
Use and the 2010 Affordable Care Act; future changes in tax
legislation and initiatives in the healthcare industry; undetected
errors in our products; the possibility of interruption at our data
centers; risks related to third party vendors; risks related to
obtaining and integrating third-party licensed technology; risks
related to a security breach by third parties; risks associated with
recruitment and retention of key personnel; other litigation matters;
uncertainties associated with doing business internationally across
borders and territories; and additional risks discussed in the
Company's filings with the Securities and Exchange Commission,
including disclosures about the Company's relationship with the
Michael Bass Group since 2009. The Company is providing this
information as of the date of this release and, except as required by
applicable law, does not undertake any obligation to update any
forward-looking statements contained in this release as a result of
new information, future events or otherwise.   
CONTACT: 
Michael Selsman
Public Communications Co.
ms@publiccommunications.biz
(310) 922-7033 
 
 
Press spacebar to pause and continue. Press esc to stop.